Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice.


Journal

Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087

Informations de publication

Date de publication:
2021
Historique:
received: 16 07 2021
accepted: 07 09 2021
entrez: 14 10 2021
pubmed: 15 10 2021
medline: 11 2 2022
Statut: epublish

Résumé

Comprehensive genomic profiling (CGP) is gradually becoming an inevitable part of the everyday oncology clinical practice. The interpretation and optimal implementation of the results is one of the hot topics of modern-day oncology. According to the recent findings, uterine cancer harbors a high level of gene alterations but is still insufficiently explored. The primary goal of this project was to assess the proportion of patients with targetable mutations. Also, the aim was to define and emphasize potential opportunities as well as the problems we have faced in the first year of testing on the national level. We performed a multicentric, retrospective, nested cross-sectional analysis on the total population of Croatian patients with advanced/metastatic uterine cancer where the tumor CGP was performed during 2020. CGP of the tumor tissue of 32 patients revealed clinically relevant genomic alterations (CRGA) in 27 patients (84%) with a median of 3 (IQR 1-4) CRGA per patient. The most common CRGAs were those of phosphatide-inositol-3 kinases (PIK3) in 22 patients (69%), with 13/22 (59%) of those patients harboring PIK3CA mutation. The next most common CGRAs were ARID1A and PTEN mutations in 13 (41%) and 11 (34%) patients, respectively. Microsatellite status was determined as stable in 21 patients (66%) and highly unstable in 10 patients (31%). A high tumor mutational burden (≥10Muts/Mb) was reported in 12 patients (38%). CGP analysis reported some kind of targeted therapy for 28 patients (88%). CGP determined clinically relevant genomic alterations in the significant majority of patients with metastatic uterine cancer, defining it as a rich ground for further positioning and development of precision oncology.

Identifiants

pubmed: 34646088
doi: 10.3389/pore.2021.1609963
pii: 1609963
pmc: PMC8504363
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1609963

Informations de copyright

Copyright © 2021 Čerina, Matković, Katić, Lovasić, Šeparović, Canjko, Jakšić, Fröbe, Pleština, Bajić and Vrdoljak.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Drugs Context. 2019 Mar 25;8:212583
pubmed: 30936937
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
MMWR Morb Mortal Wkly Rep. 2018 Dec 07;67(48):1333-1338
pubmed: 30521505
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
N Engl J Med. 2014 Feb 20;370(8):734-43
pubmed: 24552320
Lancet Oncol. 2013 May;14(6):461-71
pubmed: 23602601
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Recent Results Cancer Res. 2016;208:107-136
pubmed: 27909905
Gynecol Oncol. 2019 Sep;154(3):461-466
pubmed: 31257009
Clin Cancer Res. 2002 Oct;8(10):3034-8
pubmed: 12374669
Mol Cancer Ther. 2017 Dec;16(12):2645-2655
pubmed: 29203694
JCO Precis Oncol. 2017;2017:
pubmed: 30003184
Nature. 2019 Oct;574(7776):127-131
pubmed: 31570881
Expert Rev Anticancer Ther. 2017 May;17(5):399-409
pubmed: 28338376
Gynecol Oncol. 2007 Jul;106(1):16-22
pubmed: 17574073
Lancet Oncol. 2015 Oct;16(13):1324-34
pubmed: 26342236
Chin Clin Oncol. 2017 Oct;6(5):53
pubmed: 29129093
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
N Engl J Med. 2015 Apr 30;372(18):1689-99
pubmed: 25923549
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Lancet. 2016 Apr 2;387(10026):1415-1426
pubmed: 26777916
J Clin Oncol. 2015 Nov 10;33(32):3817-25
pubmed: 26304871
Lancet Oncol. 2017 Jun;18(6):779-791
pubmed: 28438473
J Natl Cancer Inst. 2015 Sep 15;107(11):
pubmed: 26378224
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Nat Rev Genet. 2021 Aug;22(8):483-501
pubmed: 33762738
Cancer Discov. 2017 Jun;7(6):586-595
pubmed: 28365644
Nat Biotechnol. 2013 Nov;31(11):990-2
pubmed: 24213773
J Clin Oncol. 2018 May 1;36(13):1291-1299
pubmed: 29401002
Lancet Haematol. 2019 Dec;6(12):e606-e615
pubmed: 31631023
N Engl J Med. 2012 Nov;367(18):1694-703
pubmed: 23020132
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Gynecol Oncol. 2016 Apr;141(1):2-9
pubmed: 27016222
Mol Cancer Ther. 2015 Jun;14(6):1488-94
pubmed: 25852059
Lancet Oncol. 2015 Dec;16(16):e579-80
pubmed: 26678197

Auteurs

Dora Čerina (D)

Department of Oncology, School of Medicine, University Hospital Center Split, University of Split, Split, Croatia.

Višnja Matković (V)

Department of Gynecologic Oncology, University Hospital Center Zagreb, Zagreb, Croatia.

Kristina Katić (K)

Department of Gynecologic Oncology, University Hospital Center Zagreb, Zagreb, Croatia.

Ingrid Belac Lovasić (IB)

Department of Radiotherapy and Oncology, University Hospital Center Rijeka, Rijeka, Croatia.

Robert Šeparović (R)

Department of Medical Oncology, Division of Medical Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.

Ivana Canjko (I)

Department of Radiotherapy Oncology, University Hospital Center Osijek, Osijek, Croatia.

Blanka Jakšić (B)

Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.

Ana Fröbe (A)

Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.

Stjepko Pleština (S)

Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia.

Žarko Bajić (Ž)

Research Unit "Dr. Mirko Grmek", University Psychiatric Hospital "Sveti Ivan", Zagreb, Croatia.

Eduard Vrdoljak (E)

Department of Oncology, School of Medicine, University Hospital Center Split, University of Split, Split, Croatia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH